[go: up one dir, main page]

EA201990720A1 - Способы детекции нейтрализующих антител к лептину - Google Patents

Способы детекции нейтрализующих антител к лептину

Info

Publication number
EA201990720A1
EA201990720A1 EA201990720A EA201990720A EA201990720A1 EA 201990720 A1 EA201990720 A1 EA 201990720A1 EA 201990720 A EA201990720 A EA 201990720A EA 201990720 A EA201990720 A EA 201990720A EA 201990720 A1 EA201990720 A1 EA 201990720A1
Authority
EA
Eurasian Patent Office
Prior art keywords
neutralizing antibodies
methods
leptin
detecting neutralizing
detecting
Prior art date
Application number
EA201990720A
Other languages
English (en)
Inventor
Джеффри Сейлстад
Original Assignee
Эгерион Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эгерион Фармасьютикалс, Инк. filed Critical Эгерион Фармасьютикалс, Инк.
Publication of EA201990720A1 publication Critical patent/EA201990720A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В настоящем документе предусмотрены способы детекции нейтрализующих антител к лептинам, в том числе метрелептину, а также выявления субъектов, имеющих такие нейтрализующие антитела.
EA201990720A 2016-09-12 2017-09-12 Способы детекции нейтрализующих антител к лептину EA201990720A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662393632P 2016-09-12 2016-09-12
PCT/US2017/051232 WO2018049424A1 (en) 2016-09-12 2017-09-12 Methods of detecting anti-leptin neutralizing antibodies

Publications (1)

Publication Number Publication Date
EA201990720A1 true EA201990720A1 (ru) 2019-08-30

Family

ID=61559769

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990720A EA201990720A1 (ru) 2016-09-12 2017-09-12 Способы детекции нейтрализующих антител к лептину

Country Status (18)

Country Link
US (3) US10775386B2 (ru)
EP (2) EP4283304A3 (ru)
JP (2) JP7139317B2 (ru)
CN (1) CN110139663B (ru)
BR (1) BR112019004715A2 (ru)
CA (1) CA3036551A1 (ru)
DK (1) DK3509624T3 (ru)
EA (1) EA201990720A1 (ru)
ES (1) ES2959990T3 (ru)
FI (1) FI3509624T3 (ru)
HR (1) HRP20231076T1 (ru)
HU (1) HUE063647T2 (ru)
MX (1) MX2019002818A (ru)
PL (1) PL3509624T3 (ru)
PT (1) PT3509624T (ru)
RS (1) RS64850B1 (ru)
SI (1) SI3509624T1 (ru)
WO (1) WO2018049424A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3509624T3 (fi) 2016-09-12 2023-10-18 Amryt Pharmaceuticals Inc Menetelmiä neutraloivien anti-leptiini -vasta-aineiden havaitsemiseksi
CA3104120A1 (en) * 2018-06-16 2019-12-19 Board Of Regents, The University Of Texas System Weight loss regimen
KR102718808B1 (ko) * 2018-08-03 2024-10-16 브리스톨-마이어스 스큅 컴퍼니 항-약물 항체를 검출하는 방법
WO2020231992A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
CN111983226A (zh) * 2020-03-25 2020-11-24 新加坡国立大学 SARSr-CoV抗体的检测

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
WO1996023517A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5594101A (en) 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
WO1996040912A1 (en) 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
PL324284A1 (en) 1995-06-30 1998-05-11 Lilly Co Eli Methods of treating diabetes
ATE259650T1 (de) 1995-08-17 2004-03-15 Amgen Inc Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen
ATE259243T1 (de) 1995-11-22 2004-02-15 Amgen Inc Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
AU2670897A (en) 1996-04-04 1997-10-29 Amgen, Inc. Fibulin pharmaceutical compositions and related methods
WO1998006752A1 (en) * 1996-08-16 1998-02-19 The Rockefeller University A leptin binding protein and its use in methods for diagnosing and treating abnormalities of the endogenous leptin pathway
WO1998008512A1 (en) 1996-08-30 1998-03-05 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
PL332458A1 (en) 1996-09-20 1999-09-13 Hoechst Ag Application of leptin antagonists in treating insulin resistance in cases of diabeted of type ii
ES2280083T3 (es) 1996-12-20 2007-09-01 Amgen Inc. Composiciones de proteinas de fusion ob y metodos.
AU7132798A (en) 1997-04-17 1998-11-11 Amgen, Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
HUP0003428A3 (en) 1997-06-06 2001-12-28 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
AU5347099A (en) 1998-08-10 2000-03-06 Amgen, Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
CA2344623A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
PT1151102E (pt) 1999-02-12 2006-07-31 Amgen Inc Composicoes de leptina glicosilada e metodos afins
AU2002306768A1 (en) * 2001-03-20 2002-10-03 Ortho-Clinical Diagnostics, Inc. Expression profiles and methods of use
DK2219031T3 (da) 2001-10-22 2013-06-17 Amgen Inc Anvendelse af leptin til behandling af human lipoatrofi og fremgangsmåde til bestemmelse af prædisposition for behandlinngen
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
CA2507215A1 (en) * 2002-11-25 2004-06-10 Chiron Corporation Methods for treating cancer using porimin as a target
WO2004078944A2 (en) * 2003-03-05 2004-09-16 Maine Medical Center Research Institute Thrombin, soluble jaggedi, and trap and growth of stem cells
JP4754352B2 (ja) 2003-08-29 2011-08-24 株式会社リバース・プロテオミクス研究所 タンパク質の固定化方法
DE10353593A1 (de) * 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US7320868B2 (en) * 2004-03-19 2008-01-22 Arieh Gertler Leptin binding domain compositions and methods thereto
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2219664A1 (en) 2007-11-14 2010-08-25 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
GB201004058D0 (en) * 2010-03-11 2010-04-28 Consiglio Nazionale Ricerche Diagnostic assay for obesity and related disorders
CA3138758A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Highly soluble leptins
US20130266963A1 (en) * 2011-07-06 2013-10-10 Nestec S.A. Assay for detecting neutralizing autoantibodies to biologic therapy
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
BR112016009460B1 (pt) * 2013-10-31 2020-09-29 Regeneron Pharmaceuticals, Inc. Método para detectar a presença de anticorpos neutralizantes
US20180245076A1 (en) * 2015-02-27 2018-08-30 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein c-iii (apociii) expression in lipodystrophy populations
FI3509624T3 (fi) 2016-09-12 2023-10-18 Amryt Pharmaceuticals Inc Menetelmiä neutraloivien anti-leptiini -vasta-aineiden havaitsemiseksi

Also Published As

Publication number Publication date
EP3509624A1 (en) 2019-07-17
JP7139317B2 (ja) 2022-09-20
CN110139663B (zh) 2024-05-07
RS64850B1 (sr) 2023-12-29
EP4283304A2 (en) 2023-11-29
ES2959990T3 (es) 2024-02-29
HRP20231076T1 (hr) 2023-12-22
EP3509624B1 (en) 2023-08-09
SI3509624T1 (sl) 2023-12-29
US10775386B2 (en) 2020-09-15
CN110139663A (zh) 2019-08-16
EP3509624A4 (en) 2020-02-19
EP4283304A3 (en) 2024-02-28
JP2019529904A (ja) 2019-10-17
BR112019004715A2 (pt) 2019-07-16
US20230314447A1 (en) 2023-10-05
US20180074073A1 (en) 2018-03-15
US11709166B2 (en) 2023-07-25
HUE063647T2 (hu) 2024-01-28
JP2022176209A (ja) 2022-11-25
CA3036551A1 (en) 2018-03-15
WO2018049424A1 (en) 2018-03-15
US20200378988A1 (en) 2020-12-03
JP7509834B2 (ja) 2024-07-02
PL3509624T3 (pl) 2024-03-25
FI3509624T3 (fi) 2023-10-18
PT3509624T (pt) 2023-08-28
MX2019002818A (es) 2019-08-29
DK3509624T3 (da) 2023-11-13

Similar Documents

Publication Publication Date Title
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
DOP2016000252A (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
CL2016002455A1 (es) Anticuerpos multiespecíficos.
EA201790413A1 (ru) Антитела против tigit
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA201990720A1 (ru) Способы детекции нейтрализующих антител к лептину
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
UY34824A (es) Nucleósidos de espirooxetano de uracilo
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
EA201690898A1 (ru) Способы лечения таупатии
BR112016014731A2 (pt) Anticorpos anti-baff
MX2018000778A (es) Metodos para tratar trastornos mediados por hepcidinas.
IL281355B (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
CY1122578T1 (el) Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37